Targeting mechanisms of Siglec15-mediated immune evasion in hematologic malignancies
Novel therapeutic strategies are still needed for hematopoietic malignancies (HM), which are the most common cancers in children. Harnessing the potency of the immune system has great promise for some of these patients, but limitations in available approaches remain. Our long-term goal is to develop novel therapeutic strategies for HM based on a greater understanding of the mechanisms of immune evasion. The objective of this project is to investigate a novel therapeutic target for HM, Siglec15 (Sig15).